AMRN - Amarin Corporation plc
| Previous Close | 3.040 |
| Open | 3.150 |
| Bid | 3.060 x 4000 |
| Ask | 3.070 x 3100 |
| Day's Range | 3.060 - 3.180 |
| 52 Week Range | 2.660 - 4.600 |
| Volume | 984,607 |
| Avg. Volume | 2,091,417 |
| Market Cap | 899.835M |
| Beta | 1.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.251 |
| Earnings Date | May 4, 2017 - May 8, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.60 |
- Benzinga•6 hours ago
Benzinga's Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck's Cancer Drug Review Extended
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks Here are the biotech stocks that were hitting 52-week highs May 24: ArQule, Inc. (NASDAQ: ARQL ) Baxter ...
- GlobeNewswire•23 hours ago
Amarin Announces Patent Litigation Settlement Agreement with Teva
BEDMINSTER, N.J. and DUBLIN, Ireland, May 24, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today a settlement agreement with Teva Pharmaceuticals USA, Inc. (Teva) that resolves Amarin’s previously reported Vascepa® (icosapent ethyl) patent litigation as it relates to Teva’s abbreviated new drug application seeking U.S. Food and Drug Administration (FDA) approval of generic forms of Vascepa (icosapent ethyl) capsules. This patent litigation continues in the United States District Court for the District of Nevada with parties West-Ward Pharmaceuticals Corp. and Dr. Reddy’s Laboratories, Inc. and their affiliated entities.
- GlobeNewswire•2 days ago
Amarin to Present at the Jefferies Global Healthcare Conference
Amarin Corporation plc (AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present a general company update at the Jefferies Global Healthcare Conference in New York City on Thursday, June 7, 2018, at 8:00 a.m. EDT. Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl), Amarin's first FDA-approved product, is a highly-pure, omega-3 fatty acid product available by prescription. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.
- Zacks•4 days ago
Is the Options Market Predicting a Spike in Amarin (AMRN) Stock?
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
- Thomson Reuters StreetEvents•16 days ago
Edited Transcript of AMRN earnings conference call or presentation 2-May-18 11:30am GMT
Q1 2018 Amarin Corporation PLC Earnings Call
- Associated Press•23 days ago
Amarin: 1Q Earnings Snapshot
The Dublin-based company said it had a loss of 8 cents per share. Losses, adjusted for stock option expense, were 7 cents per share. The results met Wall Street expectations. The average estimate of three ...
- GlobeNewswire•23 days ago
Amarin Reports First Quarter 2018 Financial Results and Provides Update on Operations
REDUCE-IT Study On-Track for Reporting Top-Line Results by the End of Q3 2018. Management to Host Conference Call at 7:30 a.m. ET Today. BEDMINSTER, N.J. and DUBLIN, Ireland, May 02, 2018-- Amarin Corporation ...
- Motley Fool•24 days ago
3 Stocks That Could Put Tesla's Returns to Shame
Tesla has made investors a lot of money in recent years. Here are three new stocks we think could do the same for investors going forward.
- GlobeNewswire•29 days ago
Amarin To Report First Quarter 2018 Results and Host Conference Call On May 2, 2018
BEDMINSTER, N.J. and DUBLIN, Ireland, April 26, 2018-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...
- Zacks•last month
Are Options Traders Betting on a Big Move in Amarin (AMRN) Stock?
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
- GlobeNewswire•last month
Amarin Announces Promotion of Aaron Berg to Position of Chief Commercial Officer
BEDMINSTER, N.J., and DUBLIN, Ireland, April 23, 2018-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...
- GlobeNewswire•last month
New Research: Key Drivers of Growth for Amarin, Korea Electric Power, Star Bulk Carriers, 1-800 FLOWERS.COM, Clementia Pharmaceuticals, and Bank of Nova Scotia — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, April 13, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- GlobeNewswire•last month
Amarin Sponsors Three Scientific Presentations Scheduled for National Lipid Association Scientific Sessions
BEDMINSTER, N.J. and DUBLIN, Ireland, April 12, 2018-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...
- Zacks•last month
Moving Average Crossover Alert: Amarin (AMRN)
Amarin Corporation plc (AMRN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
- GlobeNewswire•last month
Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin-Treated Patients with Reduced Kidney Function and Persistent High Triglycerides
BEDMINSTER, N.J. and DUBLIN, Ireland, April 12, 2018-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...
- ACCESSWIRE•2 months ago
Wired News – Amarin’s REDUCE-IT Study Reached 100% Mark for Estimated Onset of Targeted Primary MACE
Stock Monitor: Pernix Therapeutics Holdings Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 6, 2018 / Active-Investors.com has just released a free research report on Amarin Corp. PLC (NASDAQ: ...
- Motley Fool•2 months ago
Boom-or-Bust News Is On Tap Soon for Amarin
Amarin has needle-moving news that's fast-approaching.
- GlobeNewswire•2 months ago
Amarin Updates First Quarter Revenue Guidance, Reiterates Full Year Guidance and Updates on REDUCE-IT Cardiovascular Outcomes Study Progress and Vascepa® Promotion Initiatives
BEDMINSTER, N.J. and DUBLIN, Ireland, April 04, 2018-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...
- GlobeNewswire•2 months ago
Amarin’s REDUCE-IT Cardiovascular Outcomes Study Reaches 100% Mark for Estimated Onset of Target Primary Major Adverse Cardiovascular Events
BEDMINSTER, N.J., and DUBLIN, Ireland, April 04, 2018-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...
- Zacks•2 months ago
Implied Volatility Surging for Amarin (AMRN) Stock Options
Surging implied volatility makes Amarin (AMRN) stock lucrative to the option traders.
- Investopedia•2 months ago
7 Stocks for the Biotech Takeover Wave
Biotech M&A activity took a bit of a breather in 2017, but expect a new wave of deals in 2018.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of AMRN earnings conference call or presentation 27-Feb-18 12:30pm GMT
Q4 2017 Amarin Corporation PLC Earnings Call
- GlobeNewswire•2 months ago
Amarin Sponsors Two Scientific Presentations Scheduled for National Kidney Foundation 2018 Spring Clinical Meetings
BEDMINSTER, N.J. and DUBLIN, Ireland, March 29, 2018-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...
- GlobeNewswire•2 months ago
Amarin to Present at the H.C. Wainwright Annual Global Life Sciences Conference
BEDMINSTER, N.J. and DUBLIN, Ireland, March 28, 2018-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...
- GlobeNewswire•2 months ago
Amarin Commemorates National Triglycerides Day on March 28
BEDMINSTER, N.J. and DUBLIN, Ireland, March 27, 2018-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...
